Titre :

Clinical and economic impact of treated cmv infection in adult cmv-seropositive patients after allogeneic hematopoietic cell transplantation

Auteur(s) :

Peffault De Latour, Régis [Auteur]
Chevallier, Patrice [Auteur]
Blaise, Didier [Auteur]
Alami, Sarah [Auteur]
Levy-Bachelot, Laurie [Auteur]
Allavoine, Thierry [Auteur]
Tadmouri, Abir [Auteur]
Blomkvist, Josefin [Auteur]
Duhamel, Alain [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Srour, Micha [Auteur]
Beauvais, David [Auteur]
Hôpital Claude Huriez [Lille]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]

Titre de la revue :

Journal of Medical Virology

Nom court de la revue :

J. Med. Virol.

Numéro :

92

Pagination :

3665-3673

Éditeur :

Wiley-Blackwell

Date de publication :

2020-04-16

ISSN :

1096-9071

Mot(s)-clé(s) en anglais :

allogeneic hematopoietic stem-cell transplantation
CMV infection
cytomegalovirus
economic burden

Discipline(s) HAL :

Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Immunologie

Résumé en anglais : [en]

OBJECTIVE: Recipients of allogeneic hematopoietic stem cell transplantation (allo-HCT) with positive cytomegalovirus (CMV) serology are at increased risk of morbidity and mortality. The primary objective of this study was ...
Lire la suite >OBJECTIVE: Recipients of allogeneic hematopoietic stem cell transplantation (allo-HCT) with positive cytomegalovirus (CMV) serology are at increased risk of morbidity and mortality. The primary objective of this study was to assess the association between treated CMV infection and overall mortality within 1 year after allo-HCT in adult CMV-seropositive Recipients (R+). Secondary objectives included overall 5-year mortality after allo-HCT, risk factors for treated CMV infection, associations between treated CMV infection and allo-HCT complications and medical costs. METHODS: A multicenter retrospective cohort study was conducted in adult CMV-seropositive recipients (R+) who underwent to allo-HCT between 1st January 2010 and 31st December 2014. RESULTS: Five hundred seventy two CMV-seropositive patients (mean age, 50.2 years) undergoing allo-HCT between 2010 and 2014 were included; 55.9% of donors were CMV seropositive. CMV infection treated with antiviral therapy was reported in 227 patients (39.7%) after transplantation. One-year overall mortality was significantly increased in patients with treated CMV infections (hazard ratio, 1.86; 95% CI, 1.16-3.00; P = .011). Mean medical costs during the first post-HCT year were higher in patients with CMV infection (€46 853 vs €31 318; P < .0001). CONCLUSIONS: In this large cohort of CMV-seropositive patients undergoing allo-HCT, treated CMV infection was significantly associated with an increased 1-year risk of overall mortality, with increased length of stay and with hospitalization cost. The burden of CMV disease in allo-HCT could be reduced in the future by appropriate prophylactic strategies.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2021-07-06T12:47:25Z
2025-04-01T13:59:10Z